Vimseltinib is a medicine for tenosynovial giant cell tumor, a non-cancerous tumor that grows in joints and causes pain and stiffness. It is taken as a capsule by mouth. It works by blocking a signal that the tumor cells need to grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Romvimza (Vimseltinib) for Pigmented Villonodular Synovitis?
Vimseltinib, sold as Romvimza, is a prescription capsule for adults with tenosynovial giant cell tumor (TGCT). TGCT is a rare tumor that grows from the synovium, the soft lining inside a joint. It is considered benign because it does not behave like a typical cancer, but it can be locally aggressive: it grows into nearby tissue and causes pain, swelling and stiffness, most often in the knee. Surgery to remove the tumor is the traditional treatment, but when TGCT spreads through a joint it can be hard to remove completely, and it often comes back. Vimseltinib is approved for TGCT that is causing symptoms when surgery would likely worsen how the joint works or cause serious harm. It is not approved for children. The US Food and Drug Administration approved it in 2025.
In TGCT, some of the tumor cells make too much of a signaling protein called CSF1 (colony-stimulating factor 1). CSF1 draws in immune cells called monocytes and macrophages, and these recruited cells fuel the swelling and growth that make up much of the tumor. Vimseltinib is a kinase inhibitor, a targeted medicine that blocks a specific signaling switch inside cells. It blocks the receptor these cells use to respond to CSF1, known as the CSF1 receptor. With that signal cut off, the cells multiply less and the tumor can shrink, which in many people eases pain and stiffness. It controls the tumor rather than removing it, and it does not work for everyone.
Vimseltinib is taken by mouth twice a week, not every day. The usual dose is 30 mg, with at least 72 hours between doses, on the same two days each week. Each blister pack holds a four-week supply with the schedule printed on it, which makes it easier to keep doses spaced correctly. Capsules can be taken with or without food. Swallow them whole; do not open, break or chew them, and keep them in the blister pack until it is time for a dose. If a dose is missed by 48 hours or less, take it as soon as possible, then take the next dose on its usual day. If more than 48 hours have passed, skip the missed dose. If vomiting happens within 30 minutes of a dose, take another capsule; vomiting later than that does not call for a repeat. Side effects often lead to a short pause or a lower dose (20 mg, then 14 mg). The prescriber makes these changes based on symptoms and blood tests, so the dose should not be changed or stopped without them.
Swelling is the side effect people notice most, especially puffiness around the eyes, which affected about 6 in 10 people in the main trial. Swelling of the face or limbs, tiredness, rash and itching are also common. Some people have watery or dry eyes, higher blood pressure, or nerve symptoms such as numbness or tingling (neuropathy). These effects are often managed by pausing treatment or lowering the dose: in the trial, nearly 4 in 10 people needed a lower dose, but fewer than 1 in 20 stopped because of side effects. Routine blood tests often show changes that cause no symptoms, including higher liver enzymes (markers of liver cell irritation), higher cholesterol and lower white blood cell counts. Serious liver injury has not been seen with vimseltinib, but it has occurred with a related medicine that blocks the same receptor, so liver tests are checked regularly. Contact the care team right away about yellowing of the skin or whites of the eyes, dark urine, loss of appetite, pain on the upper right side of the abdomen, or unusual tiredness with nausea or vomiting.
Vimseltinib can harm a developing baby, based on animal studies and on how the drug works. Women who could become pregnant have a pregnancy test before starting and should use effective birth control during treatment and for 1 month after the last dose. Men whose partners could become pregnant should also use effective birth control for the same period. Tell the prescriber right away about a known or suspected pregnancy. Breastfeeding is not advised during treatment or for 1 month afterward. Vimseltinib may also reduce fertility in women and men, which is worth discussing before starting if a future pregnancy matters. Vimseltinib can raise blood levels of some other medicines, because it blocks transporter proteins that the body uses to absorb and clear certain drugs. These combinations have not been studied in people, so the usual advice is to avoid affected medicines where possible, or for some of them, to take vimseltinib at least 4 hours earlier. The prescriber and pharmacist need a complete list of prescriptions, over-the-counter medicines and supplements. People with existing liver disease or abnormal liver tests are generally not given vimseltinib. The 14 mg and 20 mg capsules contain yellow dyes (tartrazine in the 20 mg, and Sunset Yellow in both) that can cause allergic reactions, including asthma-like breathing problems, more often in people who are sensitive to aspirin. Report hives, a new rash or trouble breathing.
Vimseltinib is an ongoing treatment rather than a short course. In the main trial, results were measured after about six months. Four in 10 people taking vimseltinib had clear tumor shrinkage on scans, compared with none on placebo, and on average they had better joint movement, physical function and pain. About half had a meaningful drop in their worst pain, compared with about 1 in 5 on placebo. Most responses lasted at least six more months, and in follow-up beyond two years, about half of those who started on vimseltinib had a tumor response. Not everyone improves, and the tumor usually remains even when symptoms ease. Liver blood tests are done before starting, twice a month for the first two months, then every three months for the rest of the first year, and as needed after that. Blood tests may also show a rise in creatinine, a substance normally used to judge kidney function. With vimseltinib this rise may come from the drug slowing how the kidneys release creatinine, not from kidney damage, and it reverses after stopping, so the care team may use other tests to check the kidneys. How long to continue depends on how well the tumor responds and how side effects are tolerated; effects beyond a few years of use are still being studied.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Romvimza (Vimseltinib), what you've noticed, or ask the community a question.